NanoString’s Digital Spatial Profiling Platform Used to Create Foundational Dataset Revealing Insights into COVID-19
May 04 2021 - 3:00AM
Business Wire
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider
of life science tools for discovery and translational research,
today announced that a peer-reviewed publication using the GeoMx®
Digital Spatial Profiler (DSP) is to be published in the journal
Nature. This paper describes using the GeoMx DSP to develop a
foundational dataset to better understand the biological impact of
SARS-CoV-2 (COVD-19) infection in human lungs, which may lead to
the identification of new therapeutic interventions and prevention
strategies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210504005265/en/
RNAScope (left) was utilized to assess
the SARS-CoV-2 viral load of autopsy samples, and inform a strategy
for region of interest selection (middle). Regions showing
noteworthy biology were selected and segmented on CD45 and CD68 to
focus on specific structures within the tissues (right). (Graphic:
Business Wire)
Researchers from a network of institutions, including the Broad
Institute and Beth Israel Deaconess Medical Center (BIDMC),
Massachusetts General Hospital (MGH), the Ragon Institute of MGH,
Massachusetts Institute of Technology (MIT), Harvard, Beth Israel
Deaconess Medical Center, Brigham and Women’s Hospital, Columbia
University Irving Medical Center, and scientists at NanoString used
the GeoMx DSP to characterize autopsy lung tissue samples from
patients who had been infected by the SARS-CoV-2 virus. In
conjunction with single-cell RNA sequencing data collected for the
project, researchers utilized the Cancer Transcriptome Atlas (CTA)
and the Whole Transcriptome Atlas (WTA), with additional custom
content specific for SARS-CoV-2 genes, to produce and spatially map
a comprehensive cell-type atlas. The ability to pinpoint cellular
processes, expression pathways, and immune cell profiles in this
way offers key insights into systemic COVID-19 disease
progression.
The study, to be published in Nature and led by Aviv Regev,
Ph.D., a computational biologist and executive vice president of
Genentech Research and Early Development, and professor at the
Broad Institute of MIT and Harvard and the Department of Biology of
MIT, is entitled “COVID-19 tissue atlases reveal SARS-COV-2
pathology and cellular targets.” [Broad Institute news release]
“Spatial profiling enabled us to expand our single cell studies
and capture cellular profiles or transcriptional programs directly
in the patient tissue,” said Ioannis Vlachos, Ph.D., Co-Director of
the Bioinformatics Program, Cancer Research Institute, BIDMC, and
co-senior author of the study. “The ability to capture more than
18,000 genes in situ using the “Whole Transcriptome Atlas” was
truly transformative. We were able to understand how highly
localized phenomena, inflammation, and the presence of SARS-CoV-2
virus can affect the cellular and transcriptional landscape of the
COVID-19 lung, providing significant insights into the pathogenesis
of COVID-19.”
“This research demonstrates the value of the GeoMx Digital
Spatial Profiler in characterizing the tissue damage induced by
SARS-CoV-2 infection,” said Dr. Sarah Warren, Senior Director of
Translational Science at NanoString. “By working in partnership
with the Broad Institute, Beth Israel Deaconess Medical Center, and
other leading research centers, we have gathered meaningful
information from the scientific community, creating a dataset of
the impact of SARS CoV2 infection in multiple donors and the data
will be made publicly accessible to accelerate scientific
discovery.”
The GeoMx DSP enables researchers to rapidly and quantitatively
characterize tissue morphology with a high-throughput, high-plex
RNA and protein profiling system that preserves precious samples
for future analyses. NanoString and its collaborators have
presented DSP data in dozens of abstracts at major scientific
meetings. This publication marks the milestone of being the 50th
peer-reviewed publication, demonstrating DSP’s utility to address a
wide range of biological questions in FFPE and frozen tissues.
Interested parties can learn more about DSP by visiting
https://www.nanostring.com/scientific-content/technology-overview/digital-spatial-profiling-technology.
NanoString launched its Technology Access Program (TAP) for the
newly announced single and subcellular Spatial Molecular Imager to
complement the existing TAP program for GeoMx. Under the program, a
customer can submit tissue samples to NanoString to be analyzed
using both spatial profiling platforms and receive a complete data
package. Researchers interested in participating in NanoString’s
Technology Access Program should contact the company at
TAP@nanostring.com.
About NanoString Technologies, Inc.
NanoString Technologies is a leading provider of life science
tools for discovery and translational research. The company’s
nCounter® Analysis System is used in life sciences research and has
been cited in more than 4,000 peer-reviewed publications. The
nCounter Analysis System offers a cost-effective way to easily
profile the expression of hundreds of genes, proteins, miRNAs, or
copy number variations, simultaneously with high sensitivity and
precision, facilitating a wide variety of basic research and
translational medicine applications, including biomarker discovery
and validation. The company’s GeoMx® Digital Spatial Profiler
enables highly multiplexed spatial profiling of RNA and protein
targets in a variety of sample types, including FFPE tissue
sections. For more information, please visit
www.nanostring.com.
NanoString, NanoString Technologies, the NanoString logo, GeoMx,
and nCounter are trademarks or registered trademarks of NanoString
Technologies, Inc. in various jurisdictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210504005265/en/
Doug Farrell, NanoString Vice President, Investor
Relations & Corporate Communications dfarrell@nanostring.com Phone:
206-602-1768
NanoString Technologies (NASDAQ:NSTG)
Historical Stock Chart
From Aug 2024 to Sep 2024
NanoString Technologies (NASDAQ:NSTG)
Historical Stock Chart
From Sep 2023 to Sep 2024